Effective immunisation programmes require strategic planning that integrates the outputs of these parameters with available health facilities with the least possible disruption.

Starting with the linking of viral meningitis with Urabe based MMR vaccines in 1992.In the UK, the immunisation programme functions as a seamless service. These new roles for vaccines mean that contentious issues in immunisation will assume increasing importance. The difficulty inherent in this decision making is illustrated by the (by no means comprehensive) list of likely candidates shown in,Public confidence in the safety of vaccines is critical for the maintenance of successful immunisation programmes. After its introduction, an assessment of the safety of the M/R vaccine used in the 1994 campaign, was published by the Medicines Control Agency and provided re-assuring evidence of the absence of novel or severe events associated with its administration to over 7 million children.

This resulted from disseminated BCG infection in a child with severe combined immunodeficiency. <<65d8b475c4cc834496a586a3127d56e3>]>>

(A good example is provided by hepatitis B vaccination in the UK where two studies used the same cost estimates and yet came to opposite conclusions regarding the relative merits of mass versus targeted vaccination because of the inclusion, or not, of herd immunity effects,Responsibility to ensure that available but unused, or emerging vaccines are properly considered lies with the Communicable Disease group at DoH. These variations are often due to differences in the way healthcare systems are organized at national or regional level. One of the simplest passive reporting systems is the UK ‘Yellow Card’ system, established in 1964 in the wake of the thalidomide disaster.

An attempt has been made to do this by the National Institutes of Health in the US with their annual,There is no formal framework in the UK for assessment of the burden of disease and development of vaccines, but the PHLS does monitor trends in communicable disease epidemiology to prioritise its activities (Overview of Communicable Disease). 0000001370 00000 n Vaccination can affect transmission, either by protecting vaccinated individuals from infection or by reducing their infectivity if infected. 0000001629 00000 n Public attitudes towards immunisation are monitored through research undertaken on behalf of the Department of Health (DoH). Vaccines are usually delivered as part of carefully constructed programmes, and in this article we look at how these programmes are put together and what they aim to achieve.While a single vaccination offered to an individual has many benefits for that person, its effects don’t necessarily translate to better health outcomes for the community as a whole.

PHLS/CDSC receive samples and data from hospital laboratories throughout the country. The leaders in UK immunisation are actively involved at high level in the international vaccine policy environment (.Despite recent technical advances, there are many hurdles which limit the translation of scientific research into new vaccines. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide,This PDF is available to Subscribers Only.For full access to this pdf, sign in to an existing account, or purchase an annual subscription.Search for other works by this author on:What prevents health policy being ‘evidence-based’? The PHLS also carries out surveillance on the extent of immunity to specific diseases within the population at large, based on coverage rates of existing immunisation programmes.In addition to safety and efficacy and epidemiology of the diseases, other factors are taken into account in deciding national policy. Whereas in the past smallpox was a global epidemic costing countless lives every year, the introduction of a vaccination programme saw incidences of the disease diminish to the point where the disease no longer occurs at all.

0000000856 00000 n

Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective.Edmunds WJ. The recent furore over MMR provides an example. The biggest obstacles are economic – vaccines are used on such a wide scale that there is pressure on manufacturers to keep prices very low, even in industrialised countries, yet vaccines take as long, and cost as much to develop as conventional medicines.

0000001450 00000 n Despite all the advances in new vaccines, and the improvements in the provision of immunisation services, the greatest threat comes not from new or re-emerging infectious diseases, but from public loss of confidence in vaccine safety.Correspondence to:Dr P C L Beverley, Scientific Head, The Edward Jenner Institute for Vaccine Research, Compton, Berkshire RG20 7NN, UK.Simpson N, Lenton S, Randall R. Parental refusal to have children immunised: extent and reasons.White JM, Gillam SJ, Begg NT, Farrington CP. Contact with patients or work in clinical areas of hospitals 4.

0000008163 00000 n Such databases are available in some Canadian provinces, such as Manitoba, and in health maintenance organisations in the US such as Kaiser Permanente, covering a large proportion of the private care population of California.